Finance

Beta
Lists
AXSM:NASDAQ
Axsome Therapeutics Inc
$239.15
+0.52%
(+1.23) 1D
Jun 25, 9:53:25 AM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for AXSM...
Open
$238.83
High
$239.90
Low
$236.60
Mkt. cap
12.25B
Avg. vol.
701.90K
Volume
21.28K
52-wk high
$260.19
52-wk low
$96.09
EPS
-$3.74
Beta
0.61
Shares outstanding
51.46M
No. of employees
1K
Open
$238.83
High
$239.90
Low
$236.60
Mkt. cap
12.25B
Avg. vol.
701.90K
Volume
21.28K
52-wk high
$260.19
52-wk low
$96.09
EPS
-$3.74
Beta
0.61
Shares outstanding
51.46M
No. of employees
1K
News stories
From sources across the web
About Axsome Therapeutics Inc
CEOHerriot Tabuteau
Employees1.22K
Founded2012
Headquarters-
SectorPharmaceutical industry
Websiteaxsome.com
Analyst Ratings
Based on 17 analysts giving stock ratings to AXSM in the past 3 months
Strong Buy
Buy
16
Hold
1
Sell
0
12 month forecast
Based on 17 Wall Street analysts offering 12 month price targets for AXSM in the last 3 months.
Highest
Current $239.15
$310.00 (+29.63%)
Average
$266.69 (+11.52%)
Lowest
$200.00 (-16.37%)
Analyst
Recommendation
Action
Price Target
Projected
Date
David Amsellem
Piper Sandler
Buy
Reiterated
$258.00
+7.9%
06/17/2026
Joseph Thome
TD Cowen
Buy
Maintained
$300.00
+25.4%
06/17/2026
Benjamin Burnett
Wells Fargo
Buy
Maintained
$255.00
+6.6%
06/10/2026
Graig Suvannavejh
Mizuho Securities
Buy
Reiterated
$310.00
+29.6%
06/04/2026
Ram Selvaraju
H.C. Wainwright
Buy
Reiterated
$290.00
+21.3%
06/04/2026
Myles Minter
William Blair
Buy
Reiterated
-
-
06/04/2026
Ami Fadia
Needham
Buy
Reiterated
$267.00
+11.6%
05/06/2026
Leonid Timashev
RBC Capital
Buy
Maintained
$302.00
+26.3%
05/05/2026
Sean Laaman
Morgan Stanley
Hold
Reiterated
$242.00
+1.2%
05/05/2026
Brian Skorney
Robert W. Baird
Buy
Maintained
$246.00
+2.9%
05/05/2026
Jason Gerberry
Bank of America Securities
Buy
Reiterated
$276.00
+15.4%
05/04/2026
Yatin Suneja
Guggenheim
Buy
Maintained
$260.00
+8.7%
05/04/2026
Pete Stavropoulos
Cantor Fitzgerald
Buy
Maintained
$272.00
+13.7%
05/04/2026
David Hoang
Deutsche Bank
Buy
Reiterated
$280.00
+17.1%
05/05/2026
Matthew Hershenhorn
Oppenheimer
Buy
Reiterated
$250.00
+4.5%
05/01/2026
Andrew Tsai
Jefferies
Buy
Maintained
$200.00
-16.4%
05/01/2026
Ashwani Verma
UBS
Buy
Reiterated
$259.00
+8.3%
04/10/2026
Unknown Analyst
Jefferies
Buy
Maintained
$245.00
+2.4%
04/09/2026
Joon Lee
Truist Financial
Buy
Maintained
-
-
02/24/2026
Rudy Li
Wolfe Research
Buy
Initiated
$230.00
-3.8%
02/23/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
150.04M
170.99M
196.00M
191.20M
Cost of goods sold
13.45M
11.91M
12.33M
14.72M
Cost of revenue
13.45M
11.91M
12.33M
14.72M
Research and development expenses
49.54M
40.16M
48.79M
52.68M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
130.28M
150.24M
169.30M
185.00M
Operating expense
181.41M
192.00M
219.70M
239.24M
Total operating expenses
194.86M
203.92M
232.02M
253.97M
Operating income
-44.82M
-32.92M
-36.02M
-62.77M
Other non operating income
-
-
-
-
EBT including unusual items
-48.93M
-47.23M
-28.13M
-64.54M
EBT excluding unusual items
-46.65M
-34.04M
-37.20M
-63.95M
Income tax expense
-960.00K
-
430.00K
-
Effective tax rate
1.96%
-
-1.53%
-
Other operating expenses
-
-
-
-
Net income
-47.97M
-47.23M
-28.56M
-64.54M
Net profit margin
-31.97%
-27.62%
-14.57%
-33.76%
Earnings per share
-0.97
-0.94
-0.56
-1.26
Interest and investment income
2.25M
2.26M
2.04M
1.91M
Interest expense
-4.09M
-3.38M
-3.21M
-3.09M
Net interest expenses
-1.83M
-1.12M
-1.17M
-1.18M
Depreciation and amortization charges
-
-
-
-
EBITDA
-43.11M
-31.20M
-32.12M
-60.40M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer